ZCA
TLSIW icon

Zeke Capital Advisors’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Zeke Capital Advisors’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$5K Hold
66,666
– – ﹤0.01% 474
2022
Q3 		$4K Hold
66,666
– – ﹤0.01% 468
2022
Q2 		$6K Buy
+66,666
New +$12.7K ﹤0.01% 481

Other funds holding TLSIW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Zeke Capital Advisors's TLSIW Position: Q4 2022 in Review

Zeke Capital Advisors held its TriSalus Life Sciences Warrant (TLSIW) position steady in Q4 2022 at 66,666 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

Zeke Capital Advisors first reported a position in TLSIW in Q2 2022 and has held it in 3 quarters since. The position peaked at $6K in Q2 2022. 29 funds tracked by Wall St. Rank hold TLSIW as of Q4 2022.

  • Zeke Capital Advisors held 66,666 shares of TriSalus Life Sciences Warrant worth $5K as of Q4 2022.
  • Zeke Capital Advisors left its TriSalus Life Sciences Warrant share count unchanged in Q4 2022.
  • TriSalus Life Sciences Warrant made up ﹤0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #474 holding.
  • Zeke Capital Advisors first reported a position in TriSalus Life Sciences Warrant in Q2 2022 and has held it in 3 quarters since.
  • Zeke Capital Advisors's TriSalus Life Sciences Warrant position peaked at $6K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.